FDA's Pazdur To Patient Advocates: Focus On Issues That 'Drive The Show'
This article was originally published in The Pink Sheet Daily
Agency's oncology office director reflects on his wife's experience with cancer and urges patient community to tackle 'big picture issues' like clinical trial eligibility and informed consent.
You may also be interested in...
Cancer Drug Trials Could Benefit From ‘Rational’ Eligibility Criteria
US FDA drug reviewers argue that enrolling more heterogeneous patient populations could result in fewer postmarketing requirements and earlier satisfaction of pediatric study obligations.
Cancer Trials: Broader Eligibility Criteria Could Mean Novel Labeling Claims
Enrolling patients with stable brain metastases, HIV-positive status and other traditionally excluded groups could give sponsors a marketing edge, but trials should be designed to examine drug effects on such populations separately from the more traditional study population, stakeholders said.
Intercept’s OCA In NASH: When Hitting Surrogate Endpoint Is Not Enough For Accelerated Approval
Although US FDA reaffirmed its support of surrogate endpoints described in a 2018 draft guidance on NASH fibrosis, advisory committee members questioned the link to clinical benefit and said obeticholic acid’s serious risks made it difficult to consider the effect on the surrogate in a vacuum.